Indee Labs
Hydropore™
2018
Research, Concept, Development, Electronics Engineering + Prototype
Indee Labs: Hydropore™
µVS Delivery System™: A Cell-Engineering Platform for the Discovery, Development and Manufacturing of Modified Immune Cells.
Biotechnology Device Development — Research Use Only (RUO)
Hydropore™ (Genome Editing and Trangene Insertion) is a non-viral, platform technology using hydrodynamic conditions termed microfluidic vortex shedding (μVS) to gently permeabilize cells, allowing for quick and efficient delivery of payloads such as DNA, mRNA, and CRISPR Cas9-RNPs into immune cells for gene-editing applications. Indee Labs patented technology is a robust alternative to electroporation and viral transduction that addresses current industry challenges in cell therapy manufacturing. Utilising the Indee Labs cell-engineering platform researchers and companies can circumvent high development costs, long lead times, and yield millions of high-quality, engineered cells with minimal impact on cell viability and function. Our working relationship with biotechnology startup Indee Labs commenced in 2018 when D+I was approached to drive the development (Industrial design, mechanical engineering + electronics design) through an ISO 13485 compliant process, as well as to enhance the usability + styling of this highly complex system. In partnership, our teams have worked on numerous projects related to the development of the Hydropore™ Research device — the end-goal is the commercial launch of a fully certified and calibrated device that can process a billion cells at a time.
Complete Product Development: Industrial Design, Mechanical Engineering + Electronics Design
Modifying cells to accelerate treatments.
Accelerating the development of cell and gene therapies to treat cancers, graft-versus-host disease, and many other indications.
The Hydropore™ µVS Delivery System™ is currently verified or in development for the rapid intracellular delivery of nucleic acids and/or protein complexes to immune cells such as T cells, Regulatory T cells, Natural Killer cells, and Tumor-Infiltrating Lymphocytes with high yield and minimal perturbation of the immune cell state. The platform will accelerate the development of cell and gene therapies to treat cancers, graft-versus-host disease, and many other indications.
Current Applications.
The entire workflow of Hydropore™ is nearly identical to that of electroporation.
Hydropore™ is currently available for Research Use Only (RUO) and is verified or in development for immune cells including T cells, Tregs and TILs, PBMCs, Natural Killer (NK) cells, cell models such as HEK293Ts & Jurkats, and more. This platform is also verified for the delivery of CRISPR-Cas9 and mRNA to donor immune cells, specifically in primary human activated CD3+ T cells. The team at Indee Labs has demonstrated revolutionary improvements over existing methods including scalability, high yield, negligible perturbation of the immune cell state along with rapid processing of research-, clinical- and commercial-scale samples with a simple workflow + small footprint.
The future of cell therapies.
Indee Labs is a biotechnology startup working with the best to develop scalable, high-yield cell engineering therapies.
Indee Labs is a biotechnology startup developing the µVS Delivery System™ for cell therapy and screening in collaboration with multiple pharmaceutical and biotechnology companies, select academics along with the National Cancer Institute and the National Institute for Allergy and Infectious Diseases. Indee Labs is backed by IndieBio/SOSV, Y Combinator, MTPConnect BioMedTech Horizons Program, Social Capital, Main Sequence Ventures, Founders Fund's FF Science among others.
